Publications by authors named "Marie-Anais Locquet"
Article Synopsis
- Activating point mutations in the MET tyrosine kinase domain are identified as oncogenic drivers in various cancers, occurring in about 0.5% of cases, particularly in certain papillary renal cell carcinomas.
- Specific mutations at positions H1094, L1195, F1200, D1228, Y1230, and M1250 were labeled as oncogenic or likely oncogenic based on genetic profiling.
- Preclinical models and patient responses indicate that these mutations may enhance sensitivity to MET inhibitors, highlighting the potential for targeted precision treatments in oncology.
Bone sarcomas are rare tumors representing 0.2% of all cancers. While osteosarcoma and Ewing sarcoma mainly affect children and young adults, chondrosarcoma and chordoma have a preferential incidence in people over the age of 40.
View Article and Find Full Text PDFIn cancer cells only, TLR3 acquires death receptor properties by efficiently triggering the extrinsic pathway of apoptosis with Caspase-8 as apical protease. Here, we demonstrate that in the absence of Caspase-8, activation of TLR3 can trigger a form of programmed cell death, which is distinct from classical apoptosis. When TLR3 was activated in the Caspase-8 negative neuroblastoma cell line SH-SY5Y, cell death was accompanied by lysosomal permeabilization.
View Article and Find Full Text PDFChordomas are rare, slow-growing tumors of the axial skeleton. These tumors are locally aggressive and refractory to conventional therapies. Radical surgery and radiation remain the first-line treatments.
View Article and Find Full Text PDF